SCHEMBL72057

SCHEMBL72057

CCOC(=O)C1CCC(OC(N2CCCC2)N2CC(N3CC(C)OC(C)C3)C2)CC1

nearest known ligand 0.37

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
MAPT P10636 2/20 0.36
POLB P06746 2/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
KDM4E B2RXH2 2/20 0.34
LIPE Q05469 2/20 0.34
RAB9A P51151 1/20 0.34
TP53 P04637 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL72056 1.00 ALDH1A1 (0.37) ALDH1A1MEN1KMT2AMAPTPOLB
SCHEMBL72033 0.92 ALDH1A1 (0.41) ALDH1A1MEN1KMT2AMAPTPOLB
Hydrochloric Acid SCHEMBL72031 0.91 ALDH1A1 (0.40) ALDH1A1MEN1KMT2AMAPTPOLB
Hydrochloric Acid SCHEMBL72032 0.91 ALDH1A1 (0.40) ALDH1A1MEN1KMT2AMAPTPOLB
Hydrochloric Acid SCHEMBL72034 0.91 ALDH1A1 (0.40) ALDH1A1MEN1KMT2AMAPTPOLB
SCHEMBL71541 0.84 ALDH1A1 (0.43) ALDH1A1MEN1KMT2AMAPTPOLB
SCHEMBL71540 0.84 ALDH1A1 (0.43) ALDH1A1MEN1KMT2AMAPTPOLB
SCHEMBL72207 0.83 ALDH1A1 (0.51) ALDH1A1MEN1KMT2AMAPTPOLB
SCHEMBL71447 0.83 ALDH1A1 (0.48) ALDH1A1MEN1KMT2AMAPTPOLB
SCHEMBL71446 0.83 ALDH1A1 (0.48) ALDH1A1MEN1KMT2AMAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130065882-A1 VLA-4 inhibitory drug MACHINAGA NOBUO (JP) 2013-03-14 US disclosed
US-20120157437-A1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-06-21 US disclosed
US-8129366-B2 VLA-4 inhibitory drug DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-03-06 US disclosed
US-20090233901-A1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157437-A1 VLA-4 INHIBITORY DRUG VCAM1, ITGB4, ITGA4 ALDH1A1 216/4885MEN1 4254/4885KMT2A 568/4885
US-20130065882-A1 VLA-4 inhibitory drug VCAM1, ITGB4, ITGA4 ALDH1A1 207/4885MEN1 4337/4885KMT2A 656/4885
US-20090233901-A1 VLA-4 INHIBITORY DRUG VCAM1, ITGB4, ITGA4 ALDH1A1 525/4885MEN1 4226/4885KMT2A 881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.